Science
Mechanism of Action
This peptide, specifically Acetyl Hexapeptide-39 in clinical contexts, acts by decreasing PCG-1α expression. This reduction subsequently diminishes preadipocyte differentiation and restricts lipid accumulation within adipose tissue, directly addressing the underlying causes of visible cellulite and smoothing irregularities at the dermo-hypodermal junction.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 Clinical studies utilizing Acetyl Hexapeptide-39 at concentrations between 0.001% and 0.005% demonstrated a reduction in adipogenesis, leading to an improvement in the appearance of visible cellulite and a smoothing effect on dermo-hypodermal junction irregularities.
Transparency
Dusting Analysis
The Formula
Formulation
Stability
Optimal stability for Acetyl Hexapeptide-39 is maintained within a pH range of 5.0 to 7.0. It should be integrated into formulations during the final phase, ensuring the temperature remains below 45 °C to preserve its integrity.
Safety
Safety Profile
Specific regulatory assessments by CIR, SCCS, or FDA for Heptapeptide-39 or Acetyl Hexapeptide-39 are not available. General peptide safety evaluations by the CIR panel suggest topical concentrations below 10 ppm are typically safe. However, caution is advised for elastin-derivative peptides, when combined with other active ingredients, or when applied to compromised skin.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Heptapeptide-39 offers a valuable, targeted approach to reduce the appearance of visible cellulite by precisely inhibiting adipogenesis.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources